research Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
GT20029 showed some hair growth improvement, but longer studies are needed for better results.
Search
for
Sort by
Research
390-420 / 1000+ resultsresearch Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
research EU Legal and Regulatory Update
The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Clinical and analytical evaluation of LC-MS methods for plasma renin activity and aldosterone
The study developed methods to measure biomarkers in mice and found differences in hormone levels linked to gut microbiota diversity and stress response.
research Impact of Clinical Response on Different Approved Doses in Japan and the United States
Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
research A Comparative study of Regulations of Cell and Gene therapy in US, EU and India
The US and EU lead in cell and gene therapy regulations with more approvals and clinical trials, while India is in early stages with fewer approvals and expedited processes.
research 11. Accelerated UIP: a special challenge
Diagnosing and treating rapidly worsening lung disease is difficult and requires better guidelines and understanding.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
research Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
research Reporting on Adverse Clinical Events
Different medications can cause serious side effects in some people.
research Industry Report
The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.
research BH06: Clinical trial of combination therapy with oral hydroxychloroquine and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia
research 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
research E-Poster
Early diagnosis, genetic testing, and innovative treatments are crucial for managing complex medical conditions.
research ODAC Chairs Reveal Challenges, High Drama in a Decade of Service
ODAC members faced intense pressure but prioritized scientific evidence in drug approval decisions.
research Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database
Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
research [Chemotherapy for advanced non-Hodgkin's lymphoma with CVP therapy].
CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.
research New drugs: Agalsidase alfa
Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research An International Multicenter, Retrospective Cohort Study of 203 Patients with Pediatric Androgenetic Alopecia
Standardized treatment protocols are needed for children with androgenetic alopecia.
research Therapy of Acute Myeloid Leukemia
Treating acute myeloid leukemia is challenging, especially in older adults, despite some advancements.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Tolerance and efficacy of a new emollient barrier cream in pediatric and adult population with mild to moderate atopic dermatitis
The new cream is safe and effective for mild to moderate atopic dermatitis.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.